<![CDATA[BGB-16673 Has Low Risk of CYP3A-Mediated Drug-Drug Interactions in Healthy Volunteers in Phase 1 Studies]]>
The investigational BTK degrader BGB-16673 demonstrated a low risk of clinically relevant CYP3A-mediated drug-drug interactions, supporting greater dosing flexibility than is typical for currently available BTK inhibitors, according to data from 2 phase 1 …